10-Q: LifeMD Reports Q2 2026 Results: Revenue Dip, Increased Expenses

LifeMD, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a net loss of $7.1 million and a 4% decrease in revenue compared to the prior year, driven by lower product sales.

Summary

• LifeMD reported a net loss of $7.1 million for the three months ended June 30, 2026, compared to a net loss of $1.1 million in the same period of 2025.
• Total revenues for the quarter decreased by 4% to $47.3 million, primarily due to a $2.0 million decrease in telehealth product revenue.
• Selling and marketing expenses increased by 27% to $28.0 million, contributing to a 10% overall increase in total operating expenses.
• The company ended the quarter with $25.1 million in cash and a negative working capital of $4.5 million.
• LifeMD has $44.6 million available under its ATM Sales Agreement and expects existing cash and potential proceeds to fund operations for at least the next 12 months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reported net loss, increased operating expenses, and negative working capital, despite some revenue stabilization.

Positives

• Gross profit as a percentage of revenues increased to 89% for the three months ended June 30, 2026, up from 86% in the prior year, due to product mix and decreased shipping costs.
• Cost of telehealth revenue decreased by 23% to $5.3 million, improving its ratio to associated revenues.
• General and administrative expenses decreased by 5% to $13.6 million, primarily due to lower stock-based compensation and legal/professional fees.
• Customer service expenses decreased by 19% to $2.6 million.
• The company has $44.6 million available under its ATM Sales Agreement, providing a potential source of funding.
• LifeMD expects its existing cash and ATM proceeds to be sufficient for at least the next 12 months.

Negatives

• Reported a net loss of $7.1 million for the three months ended June 30, 2026, a significant increase from the $1.1 million net loss in the prior year's quarter.
• Total revenues decreased by 4% to $47.3 million, primarily due to a $2.0 million decrease in telehealth product revenue.
• Selling and marketing expenses increased by 27% to $28.0 million, indicating higher customer acquisition costs.
• Total operating expenses increased by 10% to $49.1 million.
• Working capital decreased by approximately $14.8 million to a negative $4.5 million.
• The company was out of compliance with its Consolidated Interest Coverage Ratio covenant as of March 31, 2026, though a waiver was subsequently granted.

Risks

• Changes in the market acceptance of our products.
• The impact of competitive products and pricing.
• Our ability to successfully commercialize our products on a large enough scale to generate profitable operations.
• Our ability to respond to new technological developments quickly and effectively, including applications and risks of artificial intelligence (AI).
• Our ability to prevent, detect and remediate cybersecurity incidents.
• Current and potential material weaknesses in our internal control over financial reporting.
• Our need to raise additional funds in the future.

Future Outlook

The company expects that its existing cash of $25.1 million as of June 30, 2026, and net proceeds from the sale of common stock under the ATM Sales Agreement will be sufficient to fund its planned operating expenses and capital expenditure requirements for at least the next 12 months.

Management Comments

• The Company expects that its existing cash as of June 30, 2026 of $25.1 million and net proceeds from the sale of common stock under the ATM Sales Agreement will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these unaudited consolidated financial statements.
• Management believes that maintaining a dedicated affiliated provider network, integrated directly into our proprietary systems, enables consistent clinical standards, operational efficiency, and scalable care delivery across multiple specialty verticals.
• Management believes these capabilities have the potential to significantly improve operational efficiency, reduce costs, and increase the agility of our technology, products, operations, and medical teams, if we are able to mitigate accompanying risks addressed under Risk Factors.

Industry Context

StockSavvy.ai notes that LifeMD's results reflect broader trends in the telehealth and digital health sector, including increased competition, a focus on subscription models, and the integration of AI. The company's efforts to expand into primary care and specialty programs like weight management and women's health align with industry growth areas, but the reported increase in marketing spend and operating expenses highlights the cost pressures in acquiring and retaining customers in this competitive landscape.

Comparison to Industry Standards

• The increase in selling and marketing expenses to 59.30% of revenue for the three months ended June 30, 2026, is significantly higher than many established healthcare providers, suggesting aggressive customer acquisition strategies.
• The gross profit margin of 88.82% is strong, indicating efficient cost management on services delivered, but this is offset by high operating expenses.
• The company's focus on a vertically integrated model, combining telehealth, pharmacy, and AI, is a strategy seen in other innovative healthcare companies aiming for efficiency and improved patient experience.
• The reported net loss of $7.1 million for the quarter, while concerning, is not uncommon for growth-stage companies in the rapidly evolving telehealth sector that are investing heavily in expansion and technology.

Legal Proceedings

• A putative class action complaint was filed alleging violations of the Securities Exchange Act of 1934 and Rule 10b-5.
• Four putative shareholder derivative complaints were filed alleging violations of the Securities Exchange Act of 1934, breach of fiduciary duties, and other claims.
• The company does not believe these complaints will have a material adverse effect, but failure to obtain a favorable resolution could.
• The company previously identified and corrected errors related to revenue recognition and out-of-period adjustments, impacting prior financial statements.

Related Party Transactions

• WorkSimpli Software: The company paid approximately $1.8 million for software development services to CloudBoson Technologies Pvt. Ltd., a company owned by WorkSimpli's Chief Software Engineer, during the six months ended June 30, 2025.
• Consulting Agreements: Will Febbo and Naveen Bhatia received RSUs for consulting services.
• Employment Agreement: Brian Schreiber, a relative of the CEO, received an annual base salary increase to $240,000.

Stakeholder Impact

• Shareholders: The net loss, increased expenses, and negative working capital may negatively impact shareholder value. The ATM availability provides a potential dilution risk if shares are issued.
• Creditors: The company's financial performance and covenants under the Credit Agreement will be closely monitored by lenders.
• Employees: Stock-based compensation remains a significant expense, indicating continued reliance on equity incentives.
• Customers: The company continues to focus on providing accessible virtual care and pharmacy services, with efforts to integrate insurance coverage.

Next Steps

• The company expects to recognize all deferred revenue related to future performance obligations as revenue by June 30, 2027.
• The company is evaluating the impact of new accounting standards updates (ASU 2024-03 and ASU 2025-06) on its financial statements.
• Management believes its remediation plan for material weaknesses in internal control over financial reporting will continue to be executed in 2026.
• The company has not drawn any amounts under its Credit Facility as of June 30, 2026, but will need to maintain specific financial covenants starting in Q3 2026.

Key Dates

Recommendation

While LifeMD is investing in growth and has a strong gross margin, the increasing operating expenses, widening net loss, and negative working capital are significant concerns. The company's ability to achieve profitability and manage its cash burn is critical. The availability of funds through the ATM provides some short-term liquidity, but the overall financial performance warrants a cautious 'hold' stance until a clear path to profitability is demonstrated.

Keywords

telehealth, virtual care, healthcare, pharmacy, revenue, expenses, net loss, stock-based compensation